Alterity Therapeutics (PRNAD) Capital Expenditures (2009 - 2019)

Alterity Therapeutics (PRNAD) has reported Capital Expenditures for 5 consecutive years, with -$5123.2 the latest figure, recorded in Q4 2019.

• In Q4 2019, Capital Expenditures fell 118.19% year-over-year to -$5123.2; the TTM figure through Dec 2019 stood at -$26661.1 (down 70.52% YoY), while the FY2024 annual figure was -$5722.0, changed N/A from the prior year.
• Capital Expenditures came in at -$5123.2 for Q4 2019 at Alterity Therapeutics, down from -$2348.0 in the prior quarter.
• The five-year high for Capital Expenditures was -$2348.0 in Q4 2018, with the low at -$16622.8 in Q4 2016.
• Average Capital Expenditures over 4 years is -$6665.3, with a median of -$3845.1 recorded in 2017.
• Across the five-year window, Capital Expenditures surged 84.56% in 2017 and slumped 118.19% in 2019, its largest moves.
• Year by year, Capital Expenditures stood at -$16622.8 in 2016, then soared by 84.56% to -$2567.1 in 2017, then grew by 8.53% to -$2348.0 in 2018, then slumped by 118.19% to -$5123.2 in 2019.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$5123.2, -$2348.0, and -$2567.1 for Q4 2019, Q4 2018, and Q4 2017 respectively.